BACKGROUND: Little is known about the antidepressive effects of repeated intravenous ketamine infusions beyond the acute phase of treatment in patients with refractory depression. METHODS: Twelve subjects with treatment-resistant non-psychotic unipolar or bipolar major depression and suicidal ideation were given repeated (up to 6) thrice-weekly acute-phase intravenous infusions of ketamine (0.5mg/kg, administered over 100min). Those who remitted during acute-phase treatment received continuation-phase treatment that consisted of 4 weekly ketamine infusions, followed by 4 weeks of post-continuation phase follow-up (during which no further ketamine infusions were administered). Clinical measures were assessed at baseline, at 24h following each infusion, at the last acute-phase observation, and during continuation and post-continuation follow-up (acute phase remitters only). RESULTS: Of the 12 enrollees, 5 (41.7%) remitted and 7 (58.3%) responded to ketamine treatment during the acute-phase. All five subjects who remitted during the acute-phase experienced further depressive symptom improvement during continuation-phase treatment. Four subjects lost remission status during the post-continuation phase, but all were still classified as positive treatment responders at the end of the post-continuation phase. Adverse effects were generally mild and transient during acute- and continuation-phase treatment; however, one subject developed behavioral outbursts and suicide threats during follow-up while hospitalized, and one subject died by suicide several weeks after the end of follow-up. LIMITATIONS: This was an uncontrolled feasibility study with a small sample size. CONCLUSIONS: The continuation-phase administration of ketamine at weekly intervals to patients with treatment-resistant depression who remitted during acute-phase ketamine treatment can extend the duration of depressive symptom remission. The antidepressive effect of ketamine persisted for several weeks after the end of continuation-phase treatment. Our results highlight the need for close monitoring of subjects who are at high baseline risk for suicide but do not respond clinically to ketamine. CLINICALTRIALS. GOV IDENTIFIER: NCT02094898.
BACKGROUND: Little is known about the antidepressive effects of repeated intravenous ketamine infusions beyond the acute phase of treatment in patients with refractory depression. METHODS: Twelve subjects with treatment-resistant non-psychotic unipolar or bipolar major depression and suicidal ideation were given repeated (up to 6) thrice-weekly acute-phase intravenous infusions of ketamine (0.5mg/kg, administered over 100min). Those who remitted during acute-phase treatment received continuation-phase treatment that consisted of 4 weekly ketamine infusions, followed by 4 weeks of post-continuation phase follow-up (during which no further ketamine infusions were administered). Clinical measures were assessed at baseline, at 24h following each infusion, at the last acute-phase observation, and during continuation and post-continuation follow-up (acute phase remitters only). RESULTS: Of the 12 enrollees, 5 (41.7%) remitted and 7 (58.3%) responded to ketamine treatment during the acute-phase. All five subjects who remitted during the acute-phase experienced further depressive symptom improvement during continuation-phase treatment. Four subjects lost remission status during the post-continuation phase, but all were still classified as positive treatment responders at the end of the post-continuation phase. Adverse effects were generally mild and transient during acute- and continuation-phase treatment; however, one subject developed behavioral outbursts and suicide threats during follow-up while hospitalized, and one subject died by suicide several weeks after the end of follow-up. LIMITATIONS: This was an uncontrolled feasibility study with a small sample size. CONCLUSIONS: The continuation-phase administration of ketamine at weekly intervals to patients with treatment-resistant depression who remitted during acute-phase ketamine treatment can extend the duration of depressive symptom remission. The antidepressive effect of ketamine persisted for several weeks after the end of continuation-phase treatment. Our results highlight the need for close monitoring of subjects who are at high baseline risk for suicide but do not respond clinically to ketamine. CLINICALTRIALS. GOV IDENTIFIER: NCT02094898.
Authors: Samuel T Wilkinson; Rachel B Katz; Mesut Toprak; Ryan Webler; Robert B Ostroff; Gerard Sanacora Journal: J Clin Psychiatry Date: 2018-07-24 Impact factor: 4.384
Authors: Samuel T Wilkinson; DaShaun Wright; Madonna K Fasula; Lisa Fenton; Matthew Griepp; Robert B Ostroff; Gerard Sanacora Journal: Psychother Psychosom Date: 2017-05-11 Impact factor: 17.659
Authors: Michael D Kritzer; Nicholas A Mischel; Jonathan R Young; Christopher S Lai; Prakash S Masand; Steven T Szabo; Sanjay J Mathew Journal: Ann Clin Psychiatry Date: 2022-02 Impact factor: 2.691
Authors: Jennifer Swainson; Alexander McGirr; Pierre Blier; Elisa Brietzke; Stéphane Richard-Devantoy; Nisha Ravindran; Jean Blier; Serge Beaulieu; Benicio N Frey; Sidney H Kennedy; Roger S McIntyre; Roumen V Milev; Sagar V Parikh; Ayal Schaffer; Valerie H Taylor; Valérie Tourjman; Michael van Ameringen; Lakshmi N Yatham; Arun V Ravindran; Raymond W Lam Journal: Can J Psychiatry Date: 2020-11-11 Impact factor: 4.356
Authors: Samuel T Wilkinson; Elizabeth D Ballard; Michael H Bloch; Sanjay J Mathew; James W Murrough; Adriana Feder; Peter Sos; Gang Wang; Carlos A Zarate; Gerard Sanacora Journal: Am J Psychiatry Date: 2017-10-03 Impact factor: 18.112
Authors: Nicolas A Nuñez; Boney Joseph; Mehak Pahwa; Ashok Seshadri; Larry J Prokop; Simon Kung; Kathryn M Schak; Jennifer L Vande Voort; Mark A Frye; Balwinder Singh Journal: Psychopharmacol Bull Date: 2020-09-14
Authors: Tony Ye; Mitchell J Bartlett; Matthew B Schmit; Scott J Sherman; Torsten Falk; Stephen L Cowen Journal: Front Neural Circuits Date: 2018-08-13 Impact factor: 3.492